Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

British Journal of Pharmacology

Volumn 175, Issue 2, 2018, Pages 192-222

  Berger, Nathan A ^a   Besson, Valerie C ^b   Boulares, A Hamid ^c   Bürkle, Alexander ^d   Chiarugi, Alberto ^e   Clark, Robert S ^f   Curtin, Nicola J ^g   Cuzzocrea, Salvatore ^h   Dawson, Ted M ⁱ   Dawson, Valina L ⁱ   Haskó, György ^j   Liaudet, Lucas ^k   Moroni, Flavio ^e   Pacher, Pál ^l   Radermacher, Peter ^m   Salzman, Andrew L ⁿ   Snyder, Solomon H ⁱ   Soriano, Francisco Garcia ^o   Strosznajder, Robert P ^p   Sümegi, Balázs ^q   Swanson, Raymond A ^r   Szabo, Csaba ^s   more..

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KONSTANZ   (Germany)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSITY OF MESSINA   (Italy)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l NATIONAL INSTITUTES OF HEALTH   (United States)

^m UNIVERSITY HOSPITAL ULM   (Germany)

ⁿ Radikal Therapeutics Inc   (United States)

^o UNIVERSITY OF SÃO PAULO   (Brazil)

^p MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^q UNIVERSITY OF PÉCS   (Hungary)

^r UNIVERSITY OF CALIFORNIA   (United States)

^s University of Texas Medical Branch School of Medicine   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; CEP 9722; E 7016; INO 1001; KU 0058684; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; PF 0367338; RUCAPARIB; TALAZOPARIB; UNCLASSIFIED DRUG; VELIPARIB;

ACUTE HEPATITIS; ACUTE KIDNEY FAILURE; ALCOHOL LIVER DISEASE; ASTHMA; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; DISEASES; DRUG DESIGN; DRUG INDICATION; DRUG REPOSITIONING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INFLAMMATION; MYOPATHY; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; SEPSIS; SEX DIFFERENCE; SHOCK; TRAUMATIC BRAIN INJURY; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; PROCEDURES;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; DRUG REPOSITIONING; HUMANS; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS;

EID: 85016419081     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13748     Document Type: Review

References (238)

1. Alano CC, Kauppinen TM, Valls AV, Swanson RA (2006). Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 103: 9685–9690.
2. + depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J Neurosci 30: 2967–2978.
3. Aldinucci A, Gerlini G, Fossati S, Cipriani G, Ballerini C, Biagioli T et al. (2007). A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation. J Immunol 179: 305–312.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
5. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Babur M et al. (2011). The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice. Mol Cancer Ther 10: 2320–2329.
6. Amé JC, Spenlehauer C, de Murcia G (2004). The PARP superfamily. Bioessays 26: 882–893.
7. Andrabi SA, Kim NS, Yu SW, Wang H, Koh DW, Sasaki M et al. (2006). Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci U S A 103: 18308–18313.
8. Antolín AA, Mestres J (2014). Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget 5: 3023–3028.
9. Armstrong GT, Kawashima T, Leisenring W (2014). Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 32: 1218–1227.
10. Ba X, Garg NJ (2011). Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 178: 946–955.
11. Bai P, Nagy L, Fodor T, Liaudet L, Pacher P (2015). Poly(ADP-ribose) polymerases as modulators of mitochondrial activity. Trends Endocrinol Metab 26: 75–83.
12. Banasik M, Stedeford T, Strosznajder RP (2012). Natural inhibitors of poly(ADP-ribose) polymerase-1. Mol Neurobiol 46: 55–63.
13. Bao Z, Xiong J, Li W, Chen Z, Shen H, Ying S (2015). Genomic instability in chronic airway inflammatory diseases. Biomed J 38: 117–124.
14. Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C et al. (2016). Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: a systematic review and meta-analysis. Oncotarget 7: 7629–7639.
15. Barkauskaite E, Jankevicius G, Ahel I (2015). Structures and mechanisms of enzymes employed in the synthesis and degradation of PARP-dependent protein ADP-ribosylation. Mol Cell 58: 935–946.
16. Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K et al. (2009). PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 83: 501–510.
17. Baxter P, Chen Y, Xu Y, Swanson RA (2014). Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke. Transl Stroke Res 5: 136–144.
18. Beneke S, Bürkle A (2007). Poly(ADP-ribosyl)ation in mammalian ageing. Nucleic Acids Res 35: 7456–7465.
19. Berger NA, Berger SJ, Gerson SL (1987). DNA repair, ADP-ribosylation and pyridine nucleotide metabolism as targets for cancer chemotherapy. Anticancer Drug Des 2: 203–209.
20. Besson VC (2009). Drug targets for traumatic brain injury from poly(ADP-ribose)polymerase pathway modulation. Br J Pharmacol 157: 695–704.
21. Bhatia S, Sklar C (2002). Second cancers in survivors of childhood cancer. Nat Rev Cancer 2: 124–132.
22. Bixel K, Hays JL (2015). Olaparib in the management of ovarian cancer. Pharmgenomics Pers Med 8: 127–135.
23. Bock FJ, Todorova TT, Chang P (2015). RNA regulation by poly(ADP-ribose) polymerases. Mol Cell 58: 959–969.
24. Boesten DM, de Vos-Houben JM, Timmermans L, den Hartog GJ, Bast A, Hageman GJ (2013). Accelerated aging during chronic oxidative stress: a role for PARP-1. Oxid Med Cell Longev 2013: 680414.
25. Borek C, Morgan WF, Ong A, Cleaver JE (1984). Inhibition of malignant transformation in vitro by inhibitors of poly(ADP-ribose) synthesis. Proc Natl Acad Sci U S A 81: 243–247.
26. Brambilla G, Martelli A (2006). Genotoxicity and carcinogenicity studies of antihypertensive agents. Mutat Res 612: 115–149.
27. Brambilla G, Martelli A (2009). Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat Res 681: 209–229.
28. Brambilla G, Mattioli F, Martelli A (2010). Genotoxic and carcinogenic effects of gastrointestinal drugs. Mutagenesis 25: 315–326.
29. Brambilla G, Mattioli F, Robbiano L, Martelli A (2013). Genotoxicity and carcinogenicity studies of bronchodilators and antiasthma drugs. Basic Clin Pharmacol Toxicol 112: 302–313.
30. Brunyanszki A, Szczesny B, Virág L, Szabo C (2016). Mitochondrial poly(ADP-ribose) polymerase: the wizard of Oz at work. Free Radic Biol Med 100: 257–270.
31. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913–917.
32. Buege M, Mahajan PB (2015). Clinical trials of poly(ADP-ribose) polymerase inhibitors for cancer therapy: a review. Rev Recent Clin Trials 10: 326–339.
33. Bürkle A, Brabeck C, Diefenbach J, Beneke S (2005). The emerging role of poly(ADP-ribose) polymerase-1 in longevity. Int J Biochem Cell Biol 37: 1043–1053.
34. Cantó C, Sauve AA, Bai P (2013). Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol Aspects Med 34: 1168–1201.
35. Cavone L, Chiarugi A (2012). Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis? Trends Mol Med 18: 92–100.
36. Chambon P, Weill JD, Mandel P (1963). Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 11: 39–43.
37. Chatterjee PK, Patel NS, Sivarajah A, Kvale EO, Dugo L, Cuzzocrea S et al. (2003). GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int 63: 853–865.
38. Chiarugi A (2002). Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited. Trends Pharmacol Sci 23: 122–129.
39. Cohausz O, Malanga M, Boukamp P, Althaus FR, Bürkle A (2008). Telomere length regulation by poly(ADP-ribose)polymerase-1. Nucleic Acids Res 36: 6309–6317.
40. Cohen-Armon M, Visochek L, Rozensal D, Kalal A, Geistrikh I, Klein R et al. (2007). DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 25: 297–308.
41. Coletta C, Módis K, Oláh G, Brunyánszki A, Herzig DS, Sherwood ER et al. (2014). Endothelial dysfunction is a potential contributor to multiple organ failure and mortality in aged mice subjected to septic shock: preclinical studies in a murine model of cecal ligation and puncture. Crit Care 18: 511.
42. Crafton SM, Bixel K, Hays JL (2016). PARP inhibition and gynecologic malignancies: a review of current literature and on-going trials. Gynecol Oncol 142: 588–596.
43. Curtin NJ, Szabo C (2013). Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 34: 1217–1256.
44. Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R et al. (2012). Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 135: 505–517.
45. De Vos M, Schreiber V, Dantzer F (2012). The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 84: 137–146.
46. Deeks ED (2015). Olaparib: first global approval. Drugs 75: 231–240.
47. Dhein S, Grassl M, Gerdom M, Vollroth M, Bakhtiary F, von Salisch S et al. (2015). Organ-protective effects on the liver and kidney by minocycline in small piglets undergoing cardiopulonary bypass. Naunyn Schmiedebergs Arch Pharmacol 388: 663–676.
48. Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M et al. (2016). Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 140: 199–203.
49. Drew Y (2015). The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 113: S3–S9.
50. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S et al. (2011). Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 103: 334–346.
51. D'Souza D, Thomas IM, Das BC (1992). Effect of inhibitor of poly (ADP-ribose) polymerase in blood lymphocyte cultures of untreated leprosy patients. Mutat Res 284: 251–255.
52. Du L, Zhang X, Han YY, Burke NA, Kochanek PM, Watkins SC et al. (2003). Intra-mitochondrial poly-ADP-ribosylation contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem 278: 18426–18433.
53. Du L, Bayir H, Lai Y, Zhang X, Kochanek PM, Watkins SC et al. (2004). Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway. J Biol Chem 279: 38563–38570.
54. Durkacz BW, Omidiji O, Gray DA, Shall S (1980). (ADP-ribose)n participates in DNA excision repair. Nature 283: 593–596.
55. Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ, Bao J et al. (1997). Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med 3: 1089–1095.
56. Esposito E, Mondello S, Di Paola R, Mazzon E, Italiano D, Paterniti I et al. (2011). Glutamine contributes to ameliorate inflammation after renal ischemia/reperfusion injury in rats. Naunyn Schmiedebergs Arch Pharmacol 383: 493–508.
57. Evgenov OV, Liaudet L (2005). Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock. Curr Vasc Pharmacol 3: 293–299.
58. Faraone-Mennella MR (2015). A new facet of ADP-ribosylation reactions: SIRTs and PARPs interplay. Front Biosci (Landmark Ed) 20: 458–473.
59. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917–921.
60. Fatokun AA, Dawson VL, Dawson TM (2014). Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 171: 2000–2016.
61. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123–134.
62. Gagné JP, Hendzel MJ, Droit A, Poirier GG (2006). The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol 18: 145–151.
63. García S, Conde C (2015). The role of poly(ADP-ribose) polymerase-1 in rheumatoid arthritis. Mediators Inflamm 2015: 837250.
64. Gariani K, Ryu D, Menzies KJ, Yi HS, Stein S, Zhang H et al. (2017). Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol 66: 132–141.
65. Gerace E, Pellegrini-Giampietro DE, Moroni F, Mannaioni G (2015). Poly(ADP-ribose) polymerase 1 (PARP-1) activation and Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) channels in post-ischemic brain damage: new therapeutic opportunities? CNS Neurol Disord Drug Targets 14: 636–646.
66. Ghonim MA, Pyakurel K, Ibba SV, Al-Khami AA, Wang J, Rodriguez P et al. (2015a). PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J Transl Med 13: 225.
67. Ghonim MA, Pyakurel K, Ibba SV, Wang J, Rodriguez P, Al-Khami AA et al. (2015b). PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice. Clin Sci (Lond) 129: 951–962.
68. Giansanti V, Donà F, Tillhon M, Scovassi AI (2010). PARP inhibitors: new tools to protect from inflammation. Biochem Pharmacol 80: 1869–1877.
69. Gibson BA, Kraus WL (2012). New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 13: 411–424.
70. Gibson BA, Zhang Y, Jiang H, Hussey KM, Shrimp JH, Lin H et al. (2016). Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation. Science 353: 45–50.
71. Gilad E, Zingarelli B, Salzman AL, Szabó C (1997). Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro. J Mol Cell Cardiol 29: 2585–2597.
72. Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL et al. (2017). A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res 23: 697–706.
73. Goldfarb RD, Marton A, Szabó E, Virág L, Salzman AL, Glock D (2002). Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 30: 974–980.
74. Griffin RJ, Curtin NJ, Newell DR, Golding BT, Durkacz BW, Calvert AH (1995). The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 77: 408–422.
75. Gruenbaum SE, Zlotnik A, Gruenbaum BF, Hersey D, Bilotta F (2016). Pharmacologic neuroprotection for functional outcomes after traumatic brain injury: a systematic review of the clinical literature. CNS Drugs 30: 791–806.
76. Gueguen C, Palmier B, Plotkine M, Marchand-Leroux C, Besson VC (2014). Neurological and histological consequences induced by in vivo cerebral oxidative stress: evidence for beneficial effects of SRT1720, a sirtuin 1 activator, and sirtuin 1-mediated neuroprotective effects of poly(ADP-ribose) polymerase inhibition. PLoS One 9: e87367.
77. Gunji A, Uemura A, Tsutsumi M, Nozaki T, Kusuoka O, Omura K et al. (2006). Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts. Cancer Lett 241: 87–92.
78. Ha HC, Snyder SH (1999). Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A 96: 13978–13982.
79. Hagberg H, Wilson MA, Matsushita H, Zhu C, Lange M, Gustavsson M et al. (2004). PARP1 gene disruption in mice preferentially protects males from perinatal brain injury. J Neurochem 90: 1068–1075.
80. Hauser B, Gröger M, Ehrmann U, Albicini M, Brückner UB, Schelzig H et al. (2006). The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Shock 25: 633–640.
81. Heller B, Bürkle A, Radons J, Fengler E, Jalowy A, Müller M et al. (1994). Analysis of oxygen radical toxicity in pancreatic islets at the single cell level. Biol Chem Hoppe Seyler 375: 597–602.
82. Henneman L, van Miltenburg MH, Michalak EM, Braumuller TM, Jaspers JE, Drenth AP et al. (2015). Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proc Natl Acad Sci U S A 112: 8409–8414.
83. Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F (2010). Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 35: 208–219.
84. Ibba SV, Ghonim MA, Pyakurel K, Lammi MR, Mishra A, Boulares AH (2016). Potential of inducible nitric oxide synthase as a therapeutic target for allergen-induced airway hyperresponsiveness: a critical connection to nitric oxide levels and PARP activity. Mediators Inflamm 2016: 1984703.
85. Imai S, Guarente L (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol 24: 464–471.
86. Ito S, Murphy CG, Doubrovina E, Jasin M, Moynahan ME (2016). PARP inhibitors in clinical use induce genomic instability in normal human cells. PLoS One 11: e0159341.
87. Iványi Z, Hauser B, Pittner A, Asfar P, Vassilev D, Nalos M et al. (2003). Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia. Shock 19: 415–421.
88. Jagtap P, Szabo C (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421–440.
89. Jęśko H, Strosznajder RP (2016). Sirtuins and their interactions with transcription factors and poly(ADP-ribose) polymerases. Folia Neuropathol 54: 212–233.
90. Ji Y, Tulin AV (2013). Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins. Int J Mol Sci 14: 16168–16183.
91. Jog NR, Caricchio R (2013). Differential regulation of cell death programs in males and females by poly (ADP-ribose) polymerase-1 and 17β estradiol. Cell Death Dis 4: e758.
92. Jog NR, Dinnall JA, Gallucci S, Madaio MP, Caricchio R (2009). Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation. J Immunol 182: 7297–7306.
93. Jubin T, Kadam A, Gani AR, Singh M, Dwivedi M, Begum R (2017). Poly ADP-ribose polymerase-1: beyond transcription and towards differentiation. Semin Cell Dev Biol 63: 167–179.
94. Kamboj A, Lu P, Cossoy MB, Stobart JL, Dolhun BA, Kauppinen TM et al. (2013). Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis. J Neuroinflammation 10: 49.
95. Kapoor K, Singla E, Sahu B, Naura AS (2015). PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice. Mol Cell Biochem 400: 153–162.
96. Kauppinen TM, Swanson RA (2007). The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 145: 1267–1272.
97. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY et al. (2012). Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30: 372–379.
98. Kim J, Padanilam BJ (2011). Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction. Am J Physiol Renal Physiol 301: F450–F459.
99. Kim SH, Engelhardt JI, Henkel JS, Siklós L, Soós J, Goodman C et al. (2004). Widespread increased expression of the DNA repair enzyme PARP in brain in ALS. Neurology 62: 319–322.
100. Knezevic CE, Wright G, Remsing Rix LL, Kim W, Kuenzi BM, Luo Y et al. (2016). Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem Biol 23: 1490–1503.
101. Kobayashi H, Ohno S, Sasaki Y, Matsuura M (2013). Hereditary breast and ovarian cancer susceptibility genes (review). Oncol Rep 30: 1019–1029.
102. Kofler J, Otsuka T, Zhang Z, Noppens R, Grafe MR, Koh DW et al. (2006). Differential effect of PARP-2 deletion on brain injury after focal and global cerebral ischemia. J Cereb Blood Flow Metab 26: 135–141.
103. Koh DW, Dawson TM, Dawson VL (2005). Poly(ADP-ribosyl)ation regulation of life and death in the nervous system. Cell Mol Life Sci 62: 760–768.
104. Komjáti K, Besson VC, Szabó C (2005). Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma. Curr Drug Targets CNS Neurol Disord 4: 179–194.
105. Konecny GE, Kristeleit RS (2016). PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 115: 1157–1173.
106. Kraus WL (2015). PARPs and ADP-Ribosylation: 50 Years … and Counting. Mol Cell 58: 902–910.
107. Kraus WL, Hottiger MO (2013). PARP-1 and gene regulation: progress and puzzles. Mol Aspects Med 34: 1109–1123.
108. Krietsch J, Rouleau M, Pic É, Ethier C, Dawson TM, Dawson VL et al. (2013). Reprogramming cellular events by poly(ADP-ribose)-binding proteins. Mol Aspects Med 34: 1066–1087.
109. Lai Y, Chen Y, Watkins SC, Nathaniel PD, Guo F, Kochanek PM et al. (2008). Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury. J Neurochem 104: 1700–1711.
110. Laudisi F, Sambucci M, Pioli C (2011). Poly (ADP-ribose) polymerase-1 (PARP-1) as immune regulator. Endocr Metab Immune Disord Drug Targets 11: 326–333.
111. Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G et al. (2016). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol 17: 1579–1589.
112. Lee Y, Karuppagounder SS, Shin JH, Lee YI, Ko HS, Swing D et al. (2013). Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 16: 1392–1400.
113. Lee JM, Ledermann JA, Kohn EC (2014). PARP inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol 25: 32–40.
114. Lee HS, Lee NC, Kouprina N, Kim JH, Kagansky A, Bates S et al. (2016). Effects of anticancer drugs on chromosome instability and new clinical implications for tumor-suppressing therapies. Cancer Res 76: 902–911.
115. Lehmann S, Costa AC, Celardo I, Loh SH, Martins LM (2016). Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease. Cell Death Dis 7: e2166.
116. Leichman L, Groshen S, O'Neil BH, Messersmith W, Berlin J, Chan E et al. (2016). Phase II study of olaparib (AZD-2281) after standard systemic therapies for disseminated colorectal cancer. Oncologist 21: 172–177.
117. Li N, Chen J (2014). ADP-ribosylation: activation, recognition, and removal. Mol Cells 37: 9–16.
118. Li J, McCullough LD (2009). Sex differences in minocycline-induced neuroprotection after experimental stroke. J Cereb Blood Flow Metab 29: 670–674.
119. Li X, Klaus JA, Zhang J, Xu Z, Kibler KK, Andrabi SA et al. (2010). Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia. J Neurochem 113: 1012–1022.
120. Li B, Luo C, Chowdhury S, Gao ZH, Liu JL (2013). Parp1 deficient mice are protected from streptozotocin-induced diabetes but not caerulein-induced pancreatitis, independent of the induction of Reg family genes. Regul Pept 186: 83–91.
121. Liaudet L, Szabó G, Szabó C (2003). Oxidative stress and regional ischemia-reperfusion injury: the peroxynitrite-poly(ADP-ribose) polymerase connection. Coron Artery Dis 14: 115–122.
122. Lord CJ, Ashworth A (2016). BRCAness revisited. Nat Rev Cancer 16: 110–120.
123. Lucarini L, Durante M, Lanzi C, Pini A, Boccalini G, Calosi L et al. (2016). HYDAMTIQ, a selective PARP-1 inhibitor, improves bleomycin-induced lung fibrosis by dampening the TGF-β/SMAD signalling pathway. J Cell Mol Med 20: 1–12.
124. Lupo B, Trusolino L (2014). Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 1846: 201–215.
125. Mabley JG, Horváth EM, Murthy KG, Zsengellér Z, Vaslin A, Benko R et al. (2005). Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther 315: 812–820.
126. Maier C, Scheuerle A, Hauser B, Schelzig H, Szabó C, Radermacher P et al. (2007). The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury. Intensive Care Med 33: 845–850.
127. Mangerich A, Bürkle A (2012). Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation. Oxid Med Cell Longev 2012: 321653.
128. Martínez-Bosch N, Iglesias M, Munné-Collado J, Martínez-Cáceres C, Moreno M, Guerra C et al. (2014). Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer. J Pathol 234: 214–227.
129. Martin-Hernandez K, Rodriguez-Vargas JM, Schreiber V, Dantzer F (2017). Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Semin Cell Dev Biol 63: 92–101.
130. Martin-Oliva D, O'Valle F, Munoz-Gamez JA, Valenzuela MT, Nunez MI, Aguilar M et al. (2004). Crosstalk between PARP-1 and NF-nB modulates the promotion of mskin neoplasia. Oncogene 23: 5275–5283.
131. Martin-Oliva D, Aguilar-Quesada R, O'Valle F, Munoz-Gamez JA, Martinez-Romero R, del Moral RG (2006). Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res 66: 5744–5756.
132. Mashimo M, Kato J, Moss J (2014). Structure and function of the ARH family of ADP-ribosyl-acceptor hydrolases. DNA Repair (Amst) 23: 88–94.
133. Masutani M, Fujimori H (2013). Poly(ADP-ribosyl)ation in carcinogenesis. Mol Aspects Med 34: 1202–1216.
134. Masutani M, Nakagama H, Sugimura T (2003). Poly (ADP-ribose) and carcinogenesis. Genes Chromosomes Cancer 38: 339–348.
135. Matsuura S, Egi Y, Yuki S, Horikawa T, Satoh H, Akira T (2011). MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model. Brain Res 1410: 122–131.
136. McCullough LD, Zeng Z, Blizzard KK, Debchoudhury I, Hurn PD (2005). Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection. J Cereb Blood Flow Metab 25: 502–512.
137. Moretti A, Ferrari F, Villa RF (2015). Neuroprotection for ischaemic stroke: current status and challenges. Pharmacol Ther 146: 23–34.
138. Moroni F (2008). Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin Pharmacol 8: 96–103.
139. Moroni F, Cozzi A, Chiarugi A, Formentini L, Camaioni E, Pellegrini-Giampietro DE et al. (2012). Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase. Br J Pharmacol 165: 1487–1500.
140. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H et al. (2009). A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 27: 359–364.
141. Mota RA, Sánchez-Bueno F, Saenz L, Hernández-Espinosa D, Jimeno J, Tornel PL et al. (2005). Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury. Lab Invest 85: 1250–1262.
142. Mota R, Sánchez-Bueno F, Berenguer-Pina JJ, Hernández-Espinosa D, Parrilla P, Yélamos J (2007). Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury. Br J Pharmacol 151: 998–1005.
143. Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Canto C et al. (2013). The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154: 430–441.
144. Mukhopadhyay P, Horváth B, Kechrid M, Tanchian G, Rajesh M, Naura AS et al. (2011). Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury. Free Radic Biol Med 51: 1774–1788.
145. Mukhopadhyay P, Rajesh M, Cao Z, Horváth B, Park O, Wang H et al. (2014). Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis. Hepatology 59: 1998–2009.
146. Mukhopadhyay P, Horváth B, Rajesh M, Varga VZ, Gariani K, Ryu D et al. (2017). PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol 66: 589–600.
147. Murakami K, Enkhbaatar P, Shimoda K, Cox RA, Burke AS, Hawkins HK et al. (2004). Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock 21: 126–133.
148. Nabavi SF, Sureda A, Habtemariam S, Nabavi SM (2015). Ginsenoside Rd and ischemic stroke; a short review of literatures. J Ginseng Res 39: 299–303.
149. Naura AS, Kim H, Ju J, Rodriguez PC, Jordan J, Catling AD et al. (2013). Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor κB-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase. J Biol Chem 288: 1458–1468.
150. Nozaki T, Fujihara H, Watanabe M, Tsutsumi M, Nakamoto K, Kusuoka O et al. (2003). Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane. Cancer Sci 94: 497–500.
151. Ogawa K, Masutani M, Kato K, Tang M, Kamada N, Suzuki H et al. (2006). Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice. Cancer Lett 236: 32–38.
152. Oláh G, Szczesny B, Brunyánszki A, López-García IA, Gerö D, Radák Z et al. (2015). Differentiation-associated downregulation of poly(ADP-ribose) polymerase-1 expression in myoblasts serves to increase their resistance to oxidative stress. PLoS One 10: e0134227.
153. Opal SM, Cross AS (1999). Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 13: 285–297.
154. O'Sullivan Coyne G, Chen A, Kummar S (2015). Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Curr Opin Oncol 27: 475–481.
155. O'Valle F, Gomez-Morales M, Del Moral RM, Seron D, Moreso F, Osuna A et al. (2007). Poly(ADP-ribose) polymerase expression in kidney transplantation: from alfa (alpha) to omega (omega). Transplant Proc 39: 2099–2101.
156. Pacher P, Szabo C (2008). Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am J Pathol 173: 2–13.
157. Parkes EE, Kennedy RD (2016). Clinical application of poly(ADP-ribose) polymerase inhibitors in high-grade serous ovarian cancer. Oncologist 21: 586–593.
158. Pascal JM, Ellenberger T (2015). The rise and fall of poly(ADP-ribose): an enzymatic perspective. DNA Repair (Amst) 32: 10–16.
159. Pears CJ, Couto CA, Wang HY, Borer C, Kiely R, Lakin ND (2012). The role of ADP-ribosylation in regulating DNA double-strand break repair. Cell Cycle 11: 48–56.
160. Penning TD (2010). Small-molecule PARP modulators – current status and future therapeutic potential. Curr Opin Drug Discov Devel 13: 577–586.
161. Pic E, Gagné JP, Poirier GG (2011). Mass spectrometry-based functional proteomics of poly(ADP-ribose) polymerase-1. Expert Rev Proteomics 8: 759–774.
162. Pieper AA, Verma A, Zhang J, Snyder SH (1999). Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20: 171–181.
163. Pillai JB, Russell HM, Raman J, Jeevanandam V, Gupta MP (2005). Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure. Am J Physiol Heart Circ Physiol 288: H486–H496.
164. Pirinen E, Cantó C, Jo YS, Morato L, Zhang H, Menzies KJ et al. (2014). Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab 19: 1034–1041.
165. Piskunova TS, Yurova MN, Ovsyannikov AI, Semenchenko AV, Zabezhinski MA, Popovich IG et al. (2008). Deficiency in poly(ADP-ribose) polymerase-1 (PARP-1) accelerates aging and spontaneous carcinogenesis in mice. Curr Gerontol Geriatr Res 2008: 754190.
166. Pommier Y, O'Connor MJ, de Bono J (2016). Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med 8: 362ps17.
167. Popoff I, Jijon H, Monia B, Tavernini M, Ma M, McKay R et al. (2002). Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J Pharmacol Exp Ther 303: 1145–1154.
168. Posavec Marjanović M, Crawford K, Ahel I (2017). PARP, transcription and chromatin modeling. Semin Cell Dev Biol 63: 102–113.
169. Ratner ES, Sartorelli AC, Lin ZP (2012). Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol 24: 564–571.
170. Riffell JL, Lord CJ, Ashworth A (2012). Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nat Rev Drug Discov 11: 923–936.
171. Rom S, Zuluaga-Ramirez V, Dykstra H, Reichenbach NL, Ramirez SH, Persidsky Y (2015). Poly(ADP-ribose) polymerase-1 inhibition in brain endothelium protects the blood-brain barrier under physiologic and neuroinflammatory conditions. J Cereb Blood Flow Metab 35: 28–36.
172. Rom S, Zuluaga-Ramirez V, Reichenbach NL, Dykstra H, Gajghate S, Pacher P et al. (2016). PARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier. J Neuroinflammation 13: 254.
173. Ryu KW, Kim DS, Kraus WL (2015). New facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases. Chem Rev 115: 2453–2481.
174. Salluzzo MG, Cosentino FI, Romano C, Scillato F, Morale MC, Rando RG et al. (2016). Poly (ADP-ribose) polymerase-1 (PARP-1) -410C/T polymorphism in Sicilian patients with Parkinson's disease. J Neurol Sci 363: 95–96.
175. Schiewer MJ, Knudsen KE (2014). Transcriptional roles of PARP1 in cancer. Mol Cancer Res 12: 1069–1078.
176. Schraufstatter IU, Hyslop PA, Hinshaw DB, Spragg RG, Sklar LA, Cochrane CG (1986). Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci U S A 83: 4908–4912.
177. Schreiber V, Dantzer F, Ame JC, de Murcia G (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517–528.
178. Schwartz JL, Morgan WF, Wolff S (1984). Reduction of sister chromatid exchange frequency with time after mutagen exposure in Chinese hamster ovary cells in the presence of 3-aminobenzamide. Environ Mutagen 6: 203–210.
179. Shall S (1983). ADP-ribosylation, DNA repair, cell differentiation and cancer. Princess Takamatsu Symp 13: 3–25.
180. Shall S, de Murcia G (2000). Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 460: 1–15.
181. Shilovsky GA, Khokhlov AN, Shram SI (2013). The protein poly(ADP-ribosyl)ation system: its role in genome stability and lifespan determination. Biochemistry (Mosc) 78: 433–444.
182. Shimoda K, Murakami K, Enkhbaatar P, Traber LD, Cox RA, Hawkins HK et al. (2003). Effect of poly(ADP ribose) synthetase inhibition on burn and smoke inhalation injury in sheep. Am J Physiol Lung Cell Mol Physiol 285: L240–L249.
183. Shiraishi Y, Tanaka Y, Kato M, Miwa M, Sugimura T (1983). Effect of poly(ADP-ribose) polymerase inhibitors on the frequency of sister-chromatid exchanges in Bloom syndrome cells. Mutat Res 122: 223–228.
184. Simbulan-Rosenthal CM, Rosenthal DS, Luo D, Li JH, Zhang J, Smulsom ME (2001). Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetrapolidity. Nucl Acid Res 29: 841–849.
185. Simmons K, Michels AW (2014). Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease. Rheum Dis Clin North Am 40: 797–811.
186. Sims JL, Berger SJ, Berger NA (1983). Poly(ADP-ribose) polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5'-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochem 22: 5188–5194.
187. Sistigu A, Manic G, Obrist F, Vitale I (2015). Trial watch – inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 3: e1053594.
188. Skyler JS, Type 1 Diabetes TrialNet Study Group (2008). Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 1150: 190–196.
189. Snyder RD, Green JW (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 488: 151–169.
190. Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR et al. (2014). Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum 43: 489–497.
191. Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M (2015). An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 12: 27–41.
192. Soriano FG, Virág L, Jagtap P, Szabó E, Mabley JG, Liaudet L et al. (2001). Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7: 108–113.
193. Soriano FG, Liaudet L, Szabó E, Virág L, Mabley JG, Pacher P et al. (2002). Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock 17: 286–292.
194. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
195. Sriram CS, Jangra A, Kasala ER, Bodduluru LN, Bezbaruah BK (2014). Targeting poly(ADP-ribose)polymerase1 in neurological diseases: a promising trove for new pharmacological interventions to enter clinical translation. Neurochem Int 76: 70–81.
196. Standiford TJ, Ward PA (2016). Therapeutic targeting of acute lung injury and acute respiratory distress syndrome. Transl Res 167: 183–191.
197. Starr ME, Saito H (2014). Sepsis in old age: review of human and animal studies. Aging Dis 5: 126–136.
198. Stoica BA, Loane DJ, Zhao Z, Kabadi SV, Hanscom M, Byrnes KR et al. (2014). PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. J Neurotrauma 31: 758–772.
199. Strosznajder RP, Czubowicz K, Jesko H, Strosznajder JB (2010). Poly(ADP-ribose) metabolism in brain and its role in ischemia pathology. Mol Neurobiol 41: 187–196.
200. Szabó C (2005). Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 52: 60–71.
201. Szabó C, Módis K (2010). Pathophysiological roles of peroxynitrite in circulatory shock. Shock 34: S4–14.
202. Szabo C, Zingarelli B, O'Connor M, Salzman AL (1996). DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc Natl Acad Sci U S A 93: 1753–1758.
203. Tallis M, Morra R, Barkauskaite E, Ahel I (2014). Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response. Chromosoma 123: 79–90.
204. Tao R, Kim SH, Honbo N, Karliner JS, Alano CC (2010). Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1. J Cardiovasc Pharmacol 56: 659–668.
205. Tao X, Chen X, Hao S, Hou Z, Lu T, Sun M et al. (2015). Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice. Neuroscience 291: 26–36.
206. Teng F, Zhu L, Su J, Zhang X, Li N, Nie Z et al. (2016). Neuroprotective effects of poly(ADP-ribose)polymerase inhibitor olaparib in transient cerebral ischemia. Neurochem Res 41: 1516–1526.
207. Ter Brugge P, Kristel PP, van der Burg E, Boon U, de Maaker M, Lips E et al. (2016). Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer. J Natl Cancer Inst 108: djw148.
208. Thomas C, Tulin AV (2013). Poly-ADP-ribose polymerase: machinery for nuclear processes. Mol Aspects Med 34: 1124–1137.
209. Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L et al. (2017). Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors. J Med Chem 60: 1262–1271.
210. To C, Kim E-H, Royce DB, Williams CR, Collins RM, Risingsong R et al. (2014). The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice. Cancer Prev Res 7: 698–707.
211. Toller IM, Altmeyer M, Kohler E, Hottiger MO, Müller A (2010). Inhibition of ADP ribosylation prevents and cures helicobacter-induced gastric preneoplasia. Cancer Res 70: 5912–5922.
212. Tong WM, Cortes U, Wang ZQ (2001). Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim Biophys Acta 1552: 27–33.
213. Ungvari Z, Sonntag WE (2014). Brain and cerebrovascular aging – new mechanisms and insights. J Gerontol A Biol Sci Med Sci 69: 1307–1310.
214. Vagnerova K, Liu K, Ardeshiri A, Cheng J, Murphy SJ, Hurn PD et al. (2010). Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway – do androgens matter? Neuroscience 166: 476–481.
215. van Lümig PP, Menting SP, van den Reek JM, Spuls PI, van Riel PL, van de Kerkhof PC et al. (2015). An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol 29: 752–760.
216. Virág L, Szabo C (2002). The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 54: 375–429.
217. Virág L, Salzman AL, Szabó C (1998). Poly(ADP-ribose) synthetase activation mediates mitochondrial injury during oxidant-induced cell death. J Immunol 161: 3753–3759.
218. Virág L, Robaszkiewicz A, Rodriguez-Vargas JM, Oliver FJ (2013). Poly(ADP-ribose) signaling in cell death. Mol Aspects Med 34: 1153–1167.
219. Vodenicharov MD, Sallmann FR, Satoh MS, Poirier GG (2000). Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1. Nucleic Acids Res 28: 3887–3896.
220. Wahlberg E, Karlberg T, Kouznetsova E, Markova N, Macchiarulo A, Thorsell AG et al. (2012). Family wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol 30: 283–288.
221. Wang DD, Li C, Sun W, Zhang S, Shalinsky DR, Kern KA et al. (2015). PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues – a population pharmacokinetic/pharmacodynamic analysis of rucaparib. Clin Pharmacol Drug Dev 4: 89–98.
222. Wang X, Wang Y, Parapanov R, Abdelnour E, Gronchi F, Perentes JY et al. (2016). Pharmacological reconditioning of marginal donor rat lungs using inhibitors of peroxynitrite and poly (ADP-ribose) polymerase during ex vivo lung perfusion. Transplant 100: 1465–1473.
223. Wei H, Yu X (2016). Functions of PARylation in DNA damage repair pathways. Genom Proteom Bioinform 14: 131–139.
224. Weidele K, Kunzmann A, Schmitz M, Beneke S, Bürkle A (2010). Ex vivo supplementation with nicotinic acid enhances cellular poly(ADP-ribosyl)ation and improves cell viability in human peripheral blood mononuclear cells. Biochem Pharmacol 80: 1103–1112.
225. Wright RH, Lioutas A, Le Dily F, Soronellas D, Pohl A, Bonet J et al. (2016). ADP-ribose-derived nuclear ATP synthesis by NUDIX5 is required for chromatin remodeling. Science 352: 1221–1225.
226. Wu Y, Chen Y, Wu Q, Jia L, Du X (2015). Minocycline inhibits PARP-1 expression and decreases apoptosis in diabetic retinopathy. Mol Med Rep 12: 4887–4894.
227. Xu JC, Fan J, Wang X, Eacker SM, Kam TI, Chen L et al. (2016). Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity. Sci Transl Med 8: 333ra48.
228. Ye K (2008). PARP inhibitor tilts cell death from necrosis to apoptosis in cancer cells. Cancer Biol Ther 7: 942–944.
229. Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T et al. (2016). Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 78: 525–531.
230. Yu J, Deng W, Wang W, Ding Y, Jin H, Chen C et al. (2012). Inhibition of poly(ADP-ribose) polymerase attenuates acute kidney injury in sodium taurocholate-induced acute pancreatitis in rats. Pancreas 41: 1299–1305.
231. Yu J, Zuo T, Deng W, Shi Q, Ma P, Chen C et al. (2016). Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis. BMC Gastroenterol 16: 81.
232. Yuan M, Siegel C, Zeng Z, Li J, Liu F, McCullough LD (2009). Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke. Exp Neurol 217: 210–218.
233. Zaremba T, Thomas H, Cole M, Plummer ER, Curtin NJ (2010). Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP1) activity and expression and its implication for PARP inhibitors in clinical trials. Cancer Chemother Pharmacol 66: 807–812.
234. Zaremba T, Thomas HD, Cole M, Coulthard SA, Plummer ER, Curtin NJ (2011). Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers. Biochem J 436: 671–679.
235. Zhang J, Dawson VL, Dawson TM, Snyder SH (1994). Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 263: 687–689.
236. Zhang Y, Wang C, Tian Y, Zhang F, Xu W, Li X et al. (2016). Inhibition of poly(ADP-ribose) polymerase-1 protects chronic alcoholic liver injury. Am J Pathol 186: 3117–3130.
237. Zingarelli B, O'Connor M, Wong H, Salzman AL, Szabó C (1996). Peroxynitrite-mediated DNA strand breakage activates poly-adenosine diphosphate ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 156: 350–358.
238. Zingarelli B, Cuzzocrea S, Zsengellér Z, Salzman AL, Szabo C (1997). Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. Cardiovasc Res 36: 205–215.